Breast Cancer Disparity and Outcomes in Underserved Women
Source : https://pubmed.ncbi.nlm.nih.gov/38127658/
Women in the United States who continue to face obstacles accessing health care are frequently termed an underserved population . Safety-net health care systems play a crucial role in mitigating...
Mortality rates of Black women were ≤2.6 times higher than those of non-Hispanic White women aged ≤50 years, whereas they were ≤1.2 times higher in Black women versus non-Hispanic White women aged >70 years.
Clinical Considerations of CDK4/6 Inhibitors in HER2 Positive Breast Cancer
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10824891/
Deregulation of cell cycles can result in a variety of cancers, including breast cancer (BC). In fact, abnormal regulation of cell cycle pathways is often observed in breast cancer, leading...
Combination therapy with CDK4/6 inhibition and anti-HER2 targeting can overcome anti-HER2 resistance, synergistically inhibiting cell proliferation, controlling tumor growth in vivo, and delaying tumor recurrence.
Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy
Source : https://pubmed.ncbi.nlm.nih.gov/38294179/
1 TECHNICAL EFFICACY: Stage 4.
Median surface/average anisotropy of the peritumoral region, measured after 2 and 4 cycles of neoadjuvant systemic treatment, increased in patients with pathologic CRs and decreased in patients with nonpathologic CRs.
Abemaciclib as Adjuvant Treatment for High-Risk Early Breast Cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38114413/
The results of the pivotal trial are sufficient to consider abemaciclib as adjuvant treatment for high-risk early breast cancer in highly selected patients. However, in order to the efficacy results...
With a median follow-up of 15.5 months, abemaciclib plus endocrine therapy demonstrated a statistically significant improvement in invasive disease-free survival versus endocrine therapy alone.
-
Albert Dekker2yrwe need more data on patient selection; I have talk to 5 different KOL about Verzenio in BRCA positive population and got 5 different answers
First-Line CDK4/6 Inhibitor-Based Combinations for HR+/HER2- Advanced Breast Cancer: a Bayesian Network Meta-Analysis
Source : https://pubmed.ncbi.nlm.nih.gov/38102891/
Ribociclib+fulvestrant probably represents the best option in a first-line setting. When combined with NSAI, dalpiciclib likely showed the best efficacy but the worst safety. Abemaciclib+NSAI and ribociclib+NSAI could also be...
Considering OS, the top 3 ranked treatments were ribociclib plus fulvestrant, abemaciclib plus NSAI, and ribociclib plus NSAI.
-
Albert Dekker2yrmany patients especially smaller petite women have the real issue with Verzenio and almost all of them need to be dose reduced at least once